348 related articles for article (PubMed ID: 11708923)
1. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.
Brady SF; Pawluczyk JM; Lumma PK; Feng DM; Wai JM; Jones R; DeFeo-Jones D; Wong BK; Miller-Stein C; Lin JH; Oliff A; Freidinger RM; Garsky VM
J Med Chem; 2002 Oct; 45(21):4706-15. PubMed ID: 12361397
[TBL] [Abstract][Full Text] [Related]
3. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
Khan SR; Denmeade SR
Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
5. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
[TBL] [Abstract][Full Text] [Related]
6. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
7. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
Akinboye ES; Rosen MD; Bakare O; Denmeade SR
Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
[TBL] [Abstract][Full Text] [Related]
8. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
Denmeade SR; Nagy A; Gao J; Lilja H; Schally AV; Isaacs JT
Cancer Res; 1998 Jun; 58(12):2537-40. PubMed ID: 9635575
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer.
DiPaola RS; Rinehart J; Nemunaitis J; Ebbinghaus S; Rubin E; Capanna T; Ciardella M; Doyle-Lindrud S; Goodwin S; Fontaine M; Adams N; Williams A; Schwartz M; Winchell G; Wickersham K; Deutsch P; Yao SL
J Clin Oncol; 2002 Apr; 20(7):1874-9. PubMed ID: 11919247
[TBL] [Abstract][Full Text] [Related]
10. Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA).
Jiang Y; Hu L
Bioorg Med Chem; 2013 Dec; 21(23):7507-14. PubMed ID: 24139844
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Tsurumi C; Abu Ajaj K; Warnecke A; Unger C; Saleem T; Kratz F
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):14-21. PubMed ID: 21042336
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen.
Wu X; Hu L
Bioorg Med Chem; 2016 Jun; 24(12):2697-706. PubMed ID: 27156193
[TBL] [Abstract][Full Text] [Related]
14. N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity.
Fernandez AM; Van Derpoorten K; Dasnois L; Lebtahi K; Dubois V; Lobl TJ; Gangwar S; Oliyai C; Lewis ER; Shochat D; Trouet A
J Med Chem; 2001 Oct; 44(22):3750-3. PubMed ID: 11606140
[TBL] [Abstract][Full Text] [Related]
15. Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design.
Pereira SGT; Hudoklin S; Kreft ME; Kostevsek N; Stuart MCA; Al-Jamal WT
Mol Pharm; 2019 Apr; 16(4):1573-1585. PubMed ID: 30802065
[TBL] [Abstract][Full Text] [Related]
16. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Abu Ajaj K; Unger C; Warnecke A; Saleem T; El-Melegy N; Madkor H; Kratz F
Eur J Cancer; 2010 Dec; 46(18):3434-44. PubMed ID: 20933385
[TBL] [Abstract][Full Text] [Related]
18. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
19. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.
Denmeade SR; Lou W; Lövgren J; Malm J; Lilja H; Isaacs JT
Cancer Res; 1997 Nov; 57(21):4924-30. PubMed ID: 9354459
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.
Albright CF; Graciani N; Han W; Yue E; Stein R; Lai Z; Diamond M; Dowling R; Grimminger L; Zhang SY; Behrens D; Musselman A; Bruckner R; Zhang M; Jiang X; Hu D; Higley A; Dimeo S; Rafalski M; Mandlekar S; Car B; Yeleswaram S; Stern A; Copeland RA; Combs A; Seitz SP; Trainor GL; Taub R; Huang P; Oliff A
Mol Cancer Ther; 2005 May; 4(5):751-60. PubMed ID: 15897239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]